Neurophet Inc.

Founded in 2016, Neurophet is a medical technology company specializing in AI-powered brain imaging analysis and neuromodulation solutions. With a mission to solve challenges in brain diseases, Neurophet develops innovative solutions across the continuum of diagnosis, treatment guidance, and therapy. Its core businesses include AI-based brain imaging solutions for neurodegenerative diseases such as Alzheimer’s disease, imaging CRO services supporting clinical trials for drug development, and personalized neuromodulation solutions.

Neurophet has established subsidiaries in the United States and Japan and collaborates with distribution and business partners across global markets. Its products have obtained major regulatory approvals and clearances, including U.S. FDA 510(k), Japan MHLW, and Singapore HSA, with selected products CE-marked under the MDD. Neurophet continues to expand its international presence through growing commercial activities and exports worldwide.